{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:53:23Z","timestamp":1785876803250,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008920","name":"University of Saskatchewan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016628","name":"University of Saskatchewan College of Pharmacy and Nutrition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jpba.2026.117599","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:49:48Z","timestamp":1780415388000},"page":"117599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An improved method for quantification of cannabidiol, \u03949-tetrahydrocannabinol, and their metabolites in human plasma and urine"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3866-3972","authenticated-orcid":false,"given":"Ayat","family":"Zagzoog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5161-8677","authenticated-orcid":false,"given":"Deborah","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nini","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Bachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3987-3103","authenticated-orcid":false,"given":"Christopher","family":"Kudrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin L.","family":"Hurd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-2635","authenticated-orcid":false,"given":"Jane","family":"Alcorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Laprairie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117599_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fphar.2020.00124","article-title":"From Cannabis sativa to cannabidiol: promising therapeutic candidate for the treatment of neurodegenerative diseases","volume":"11","author":"Cassano","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117599_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2026.117599_bib3","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","article-title":"Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age","volume":"9","author":"Crippa","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpba.2026.117599_bib4","doi-asserted-by":"crossref","DOI":"10.7812\/TPP\/18-041","article-title":"Cannabidiol in anxiety and sleep: a large case series","volume":"23","author":"Shannon","year":"2019","journal-title":"Perm. J."},{"key":"10.1016\/j.jpba.2026.117599_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/2045125319881916","article-title":"Cannabidiol as a potential treatment for psychosis","volume":"9","author":"Davies","year":"2019","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jpba.2026.117599_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/antiox9010021","article-title":"Antioxidative and anti-inflammatory properties of cannabidiol","volume":"9","author":"Atalay","year":"2019","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jpba.2026.117599_bib7","article-title":"A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study","volume":"2","author":"Jadoon","year":"2017","journal-title":"J. C. I. Insight"},{"key":"10.1016\/j.jpba.2026.117599_bib8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/cancers14040885","article-title":"Cannabidiol (CBD) in cancer management","volume":"14","author":"O'Brien","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jpba.2026.117599_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1087011","article-title":"Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries","volume":"14","author":"Aychman","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jpba.2026.117599_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpba.2026.117599_bib11","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41386-025-02175-3","article-title":"Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial","volume":"50","author":"Chesney","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpba.2026.117599_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpba.2026.117599_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11926-022-01077-3","article-title":"Cannabidiol (CBD) in rheumatic diseases (Musculoskeletal Pain)","volume":"24","author":"Boehnke","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jpba.2026.117599_bib14","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1089\/jmf.2020.0178","article-title":"Antinociceptive and anti-inflammatory properties of cannabidiol alone and in combination with standardized bioflavonoid composition","volume":"24","author":"Yimam","year":"2021","journal-title":"J. Med. Food"},{"key":"10.1016\/j.jpba.2026.117599_bib15","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1097\/j.pain.0000000000001052","article-title":"Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis","volume":"158","author":"Philpott","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.jpba.2026.117599_bib16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpba.2026.117599_bib17","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117599_bib18","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.jpba.2026.117599_bib19","first-page":"3448","article-title":"Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines","volume":"8","author":"Zgair","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.jpba.2026.117599_bib20","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117599_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/jcm8070989","article-title":"Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use","volume":"8","author":"Brown","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jpba.2026.117599_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-030-61663-2_3","article-title":"Clinical pharmacokinetics of cannabinoids and potential drug-drug interactions","volume":"1297","author":"V\u00e1zquez","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jpba.2026.117599_bib23","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2026.117599_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","article-title":"Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug","volume":"39","author":"Zuardi","year":"2006","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.jpba.2026.117599_bib25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.amjmed.2019.05.017","article-title":"Cannabis and cannabinoids: kinetics and interactions","volume":"132","author":"Foster","year":"2019","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jpba.2026.117599_bib26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40263-020-00741-5","article-title":"Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications","volume":"34","author":"Perucca","year":"2020","journal-title":"C. N. S. Drugs"},{"key":"10.1016\/j.jpba.2026.117599_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/ph17020244","article-title":"Strategies to improve cannabidiol bioavailability and drug delivery","volume":"17","author":"O'Sullivan","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jpba.2026.117599_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/jssc.70234","article-title":"The Last 10 years of research in the enantioseparation of pharmacologically relevant phytocannabinoids: an updated review","volume":"48","author":"Varfaj","year":"2025","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2026.117599_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jms.3152","article-title":"Development and validation of an LC-MS\/MS method for quantification of \u03949-tetrahydrocannabinolic acid A (THCA-A), THC, CBN and CBD in hair","volume":"48","author":"Roth","year":"2013","journal-title":"J. Mass. Spectrom."},{"key":"10.1016\/j.jpba.2026.117599_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.forsciint.2014.07.026","article-title":"Determination of \u03949-tetrahydrocannabinolic acid A (\u03949-THCA-A) in whole blood and plasma by LC-MS\/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis","volume":"243","author":"Raikos","year":"2014","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.jpba.2026.117599_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11419-016-0344-7","article-title":"Simple protein precipitation-based analysis of \u03949-tetrahydrocannabinol and its metabolites in human serum by liquid chromatography\u2013tandem mass spectrometry","volume":"35","author":"Dziadosz","year":"2017","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.jpba.2026.117599_bib32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jpba.2017.06.003","article-title":"Pharmaceutical and biomedical analysis of cannabinoids: a critical review","volume":"147","author":"Citt","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117599_bib33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.chroma.2016.05.024","article-title":"Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry","volume":"1453","author":"Scheidweiler","year":"2016","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jpba.2026.117599_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jchromb.2016.12.038","article-title":"Dried haematic microsamples and LC-MS\/MS for the analysis of natural and synthetic cannabinoids","volume":"1044-1045","author":"Protti","year":"2017","journal-title":"J. Chromatogr. B. Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2026.117599_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.chroma.2012.11.030","article-title":"M.A. Ruggi, Dried blood spots: liquid chromatography-mass spectrometry analysis of \u03949-tetrahydrocannabinol and its main metabolites","volume":"1271","author":"Mercolini","year":"2013","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jpba.2026.117599_bib36","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jat\/28.6.464","article-title":"A fatal overdose of cocaine associated with coingestion of marijuana, buprenorphine, and fluoxetine. Body fluid and tissue distribution of cocaine and its metabolites determined by hydrophilic interaction chromatography-mass spectrometry(HILIC-MS)","volume":"28","author":"Giroud","year":"2004","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jpba.2026.117599_bib37","series-title":"Theoretical understanding and method development for high performance liquid chromatography-mass spectrometry for environmental analysis","author":"Craven","year":"2021"},{"key":"10.1016\/j.jpba.2026.117599_bib38","unstructured":"Food and Drug Administration. Bioanalytical method validation. \u3008http:\/\/www.fda\u3009. gov\/cder\/guidance\/4252fnl.pdf.2001. (accessed 28 May 2026)."},{"key":"10.1016\/j.jpba.2026.117599_bib39","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2022, May 24). Bioanalytical method validation and study sample analysis (M10). \u3008https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf\u3009 (accessed 28 May 2026)."},{"key":"10.1016\/j.jpba.2026.117599_bib40","unstructured":"Y.L. Hurd, Investigation of the Pharmacokinetic Profile of CBD - Phase 1 ANANDA. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05023070?distance=50&term=Yasmin%20Hurd&rank=5\u3009 (accessed 28 May 2026)."},{"key":"10.1016\/j.jpba.2026.117599_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116174","article-title":"Innovative LC-MS\/MS method for therapeutic drug monitoring of fenfluramine and cannabidiol in the plasma of pediatric patients with epilepsy","volume":"245","author":"Pigliasco","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117599_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2020.583404","article-title":"Pharmacokinetic and safety evaluation of various oral doses of a novel 1:20 THC:CBD Cannabis herbal extract in Dogs","volume":"7","author":"Chicoine","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.jpba.2026.117599_bib43","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/ejn.15096","article-title":"Dissociable changes in spike and wave discharges following exposure to injected cannabinoids and smoked cannabis in Genetic Absence Epilepsy Rats from Strasbourg","volume":"55","author":"Roebuck","year":"2022","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.jpba.2026.117599_bib44","article-title":"The human metabolite of cannabidiol, 7-hydroxyl cannabidiol, but not 7-carboxy cannabidiol, is anticonvulsant in the maximal electroshock seizure threshold test (MEST) in mouse","volume":"1","author":"Whalley","year":"2017","journal-title":"Am. Epilepsy Soc. Meet."},{"key":"10.1016\/j.jpba.2026.117599_bib45","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1124\/dmd.120.000350","article-title":"Cytochrome P450-catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol","volume":"49","author":"Beers","year":"2021","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.jpba.2026.117599_bib46","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jat\/bkab059","article-title":"Urinary pharmacokinetic profile of cannabidiol (CBD), \u03949-tetrahydrocannabinol (THC) and their metabolites following oral and vaporized CBD and vaporized CBD-dominant cannabis administration","volume":"46","author":"Sholler","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jpba.2026.117599_bib47","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jat\/bkac042","article-title":"Urinary excretion profile of cannabinoid analytes following acute administration of oral and vaporized cannabis in infrequent cannabis users","volume":"46","author":"Sholler","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jpba.2026.117599_bib48","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1007\/s00216-013-6837-x","article-title":"Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine","volume":"405","author":"Bergamaschi","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2026.117599_bib49","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00414-018-01994-y","article-title":"Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a \"tobacco substitute\"","volume":"133","author":"H\u00e4dener","year":"2019","journal-title":"Int. J. Leg. Med."},{"key":"10.1016\/j.jpba.2026.117599_bib50","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/3-540-26573-2_23","article-title":"Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol","volume":"168","author":"Huestis","year":"2005","journal-title":"Handb. Exp. Pharmacol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526002670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526002670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:33:56Z","timestamp":1785875636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526002670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":50,"alternative-id":["S0731708526002670"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117599","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An improved method for quantification of cannabidiol, \u03949-tetrahydrocannabinol, and their metabolites in human plasma and urine","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117599"}}